Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients

Gynecologic Oncology

Volumn 72, Issue 2, 1999, Pages 202-207

  Cohen, Ilan ^a   Figer, Arie ^b,c   Tepper, Ron ^a   Shapira, Jeremiah ^a   Altaras, Marco M ^a   Yigael, Dror ^a   Beyth, Yoram ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hyperestrogen; Ovarian; Overstimulation; Premenopausal; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTRADIOL; FOLLITROPIN; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; OVARY CYST; OVARY HYPERSTIMULATION; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 0032941053     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5201     Document Type: Article

References (32)

1. Early Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Shulman A, Cohen I, Altaras M, Maymon R, Ben-Nun I, Tepper R, Beyth Y: Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer. Hum Reprod 9:1427-1429, 1994
3. Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without Prednisone in premenopausal breast cancer patients with metastases in one to three auxiliary lymph nodes. Cancer Res 45:4454-4459, 1985
4. Manni A, Pearson OH: Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779-785, 1980
5. Rose DP, Davis TE: Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40: 4043-4047, 1980
6. Sawka CA, Pritchard KI, Paterson DJA, et al.: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46:3152-3156, 1986
7. Ravdin PM, Fritz NF, Tormey DC, and Jordan VC: Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long term tamoxifen. Cancer Res 48:1026-1029, 1988
8. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, and Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1488-1491, 1991
9. Cohen I, Rosen DJD, Altaras MM, Beyth Y: Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian over-stimulation, cystic formations and fibroid overgrowth. Br J Cancer 69:620-621, 1994
10. Jolles CJ, Smotkin D, Ford KL, Jones KP: Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. J Reprod Med 35:299-300, 1990
11. Barbieri RL, Ferraci AL, Droesch JM, Rachelson BL: Ovarian torsion in a premenopausal woman treated with tamoxifen for breast cancer. Fertil Steril 59:459-460, 1993
12. Hochner-Celnikier D, Anteby E, Yagel S: Ovarian cysts in tamoxifen treated premenopausal women with breast cancer - a management dilemma. Am J Obstet Gynecol 172:1323-1324, 1995
13. Powels TJ, Jones AL, Ashley SE, et al.: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
14. Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S: Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol 174:141-144, 1996
15. Baum M, Brinkley DM, Dosset JA, et al.: Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer: analysis of six years by Nolvadex adjuvant trial organisation. Lancet 2:836-840, 1985
16. Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9:1283-1297, 1991
17. Welsh TH Jr, Jia TL, Jones PB, Zhuang LZ, Jsueh AJ: Disparate effects of triphenylethylene antiestrogens on estrogens and progestin biosynthesis by cultured rat granulosa cells. Endocrinology 115:1275-1282, 1984
18. Lerner LJ, Jordan WC: Development of antiestrogens and their use in breast cancer: eighth Cain Memorial award lecture. Cancer Res 50:4177-4189, 1990
19. Lippman ME, Dickson RB, Bates S: Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7:59-70, 1986
20. Lino Y, Wolf DM, Langon-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC: Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse. Br J Cancer 64:1019-1024, 1991
21. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984
22. Dabre PD, Curtis S, King RJG: Effects of estradiol and tamoxifen on human breast cancer cells in serum free culture. Cancer Res 44:2790-2793, 1984
23. Baum M, Houghton J, Riley D: Results of the cancer research campaign adjuvant trial for preoperative cyclophosphamide and long-term TAM in early breast cancer, reported at the tenth year follow up. Acta Oncol 31:251-257, 1992
24. Healey B, Tormey DC, Gray S, Taylor S, Cummings E: Arterial and venous thrombotic events in ECOG adjuvant breast cancer trials. Proc Am Oncol 5:54, 1987
25. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR: Population-based study of the tamoxifen therapy and subsequent ovarian, endometrial and breast cancer. J Natl Cancer Inst 87:1359-1364, 1995
26. Groom GC, Griffiths K: Effect of the anti-estrogen tamoxifen on plasma levels of lutenizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J Endocrinol 70:421-428, 1976
27. Spicer DV, Pike MC, Henderson BE: Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet 337:1414, 1991
28. Powels TJ, Tillyer CR, Jones AJ, Ashley SE, Treleaven J, Davel JB, et al.: Prevention of breast cancer with TAM - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26:680-684, 1990
29. Dorr FA, Friedman MA: The role of chemotherapy in the management of primary breast cancer. Cancer 41:632-644, 1991
30. Nayfield SG, Korp JE, Ford LJ, Dorr FA, Kramer BS: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991
31. Powels TJ, Ashley SE, et al.: The Royal Marsden Hospital pilot tamoxifen chemoprotective trial. Breast Cancer Res Treat 31:485-490, 1994
32. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham L, Cronin WM: Endometrial cancer in TAM-trebreast cancer patients; findings from the National Surgical Adjuvant Breast and Bowel Project. (NSABP)B-14. J Natl Cancer Inst 86:527-537, 1994